Pfizer-Backed VitaDAO Votes on Creating For-Profit Company to Fund Longevity Research

The DAOs native token, VITA, rose 3% on news the community was considering the proposal.

AccessTimeIconApr 5, 2023 at 3:46 p.m. UTC
Updated May 9, 2023 at 4:12 a.m. UTC
10 Years of Decentralizing the Future
May 29-31, 2024 - Austin, TexasThe biggest and most established global hub for everything crypto, blockchain and Web3.Register Now

Members of Pfizer-backed VitaDAO are voting on whether to create a for-profit company to secure and distribute funding for longevity research, the collective tweeted on Wednesday.

The company, to be called VitaTech, would leverage public funding to license longevity technologies developed in U.S. universities and support their continued development. The funds would come from research foundations and government grants such as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR).

  • Why Worldcoin Is Launching a Layer 2
    20:07
    Why Worldcoin Is Launching a Layer 2
  • Polymarket Traders Bet on Fed Rate Cuts; Bitcoin Spot ETFs Register Five-Day Withdrawals Streak
    02:17
    Polymarket Traders Bet on Fed Rate Cuts; Bitcoin Spot ETFs Register Five-Day Withdrawals Streak
  • Base Monthly Active Addresses Increased by 160% in March: Nansen
    00:50
    Base Monthly Active Addresses Increased by 160% in March: Nansen
  • Bitcoin Halving: We Answer Your Questions
    04:16
    Bitcoin Halving: We Answer Your Questions
  • “To make up for [VitaDAO’s funding] shortfall, we are currently discussing a proposal to establish a for-profit US-based company that will bridge the gap between research and commercialization,” the collective tweeted.

    The company will operate as a subsidiary or affiliate of VitaDAO. It also aims to serve as a launchpad for startups, helping research grant holders commercialize their tech, according to the proposal.

    The proposal will enter a 10-week execution phase between April 3 and June 12, 2023, if approved.

    VitaDAO raised $4.1 million in a funding round led by Pfizer Ventures with participation from several other investors in January. Pfizer is the first pharmaceutical company to weigh in on decentralized autonomous organization proposals and participate in the VitaDAO project’s incubation and commercialization.

    VITA inched up 3% in the past 24 hours, according to CoinDesk data.

    Edited by James Rubin.

    Disclosure

    Please note that our privacy policy, terms of use, cookies, and do not sell my personal information has been updated.

    CoinDesk is an award-winning media outlet that covers the cryptocurrency industry. Its journalists abide by a strict set of editorial policies. In November 2023, CoinDesk was acquired by the Bullish group, owner of Bullish, a regulated, digital assets exchange. The Bullish group is majority-owned by Block.one; both companies have interests in a variety of blockchain and digital asset businesses and significant holdings of digital assets, including bitcoin. CoinDesk operates as an independent subsidiary with an editorial committee to protect journalistic independence. CoinDesk employees, including journalists, may receive options in the Bullish group as part of their compensation.

    Elizabeth Napolitano

    Elizabeth Napolitano was a news reporter at CoinDesk.


    Learn more about Consensus 2024, CoinDesk's longest-running and most influential event that brings together all sides of crypto, blockchain and Web3. Head to consensus.coindesk.com to register and buy your pass now.



    Read more about